An exclusive interview with Pfizer’s Wayne Simmons on reshaping customer experience by listening to those interacting with ...

offer a new number one by pharma sales (Abbvie/Allergan), a much leaner, specialty-focused Pfizer divested of its mature Upjohn products, sold to Mylan, and a new giant in oncology (BMS/Celgene).

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the company’s pharma division was able to eke out modest sales gains of ...

A report from McKinsey shows that healthcare providers vary widely in their channel preferences and content expectations: only 31% are willing to accept regular visits from pharma sales reps ...

David Ricks, CEO of Eli Lilly, saw double-digit compensation growth that year, spurred by sales growth of its GLP-1 weight loss and diabetes drugs. The company became the biggest pharma by market ...

Verona Pharma reports $36.6 million in Ohtuvayre sales for Q4 2024, with ongoing Phase 2 trials advancing. Verona Pharma plc announced its financial results for the fourth quarter and full year of ...

In a heated competition among BTK inhibitor treatments for blood cancer, BeiGene’s third-to-market Brukinsa has for the first time surpassed AstraZeneca’s Calquence in quarterly sales.

Vertex, which makes multiple cystic fibrosis (CF) drugs, enjoys a monopoly over sales of treatments for ... biotechnology companies from pharmaceutical companies, which research and develop ...

"This positions us very well for further expansion in sales and marketing as we capitalize on our success and bring the highest quality products to market." Iris Bincovich, CEO of Innocan Pharma ...

Sun Pharmaceutical Industries Ltd aims to spend 7-8 per cent of its sales in the current fiscal on research and development activities as it looks to further strengthen its product portfolio across ...